Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Febrile

Febrile artwork

137: Cocci Me If You Can

Nov 9, 20261 hr 10 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Learn how to master management of Valley Fever with an expert Coccidioidomycosis team from the University of Arizona including Drs. Taghrid Taha, Fariba Donovan, and Thomas Erwes! Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com Febrile is produced with support from the Infectious Diseases Society of America (IDSA)

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Hi, everyone. Welcome to Febrile, a cultured podcast about all things infectious disease. We use consult questions to dive into ID clinical reasoning, diagnostics, and antimicrobial management. I'm Sara Dong, your host. Today I am joined by a team from the University of Arizona. First up is the mastermind behind this episode, Dr. Taghrid Taha. Hi, this is Taghrid Taha. I am second year ID fellow at University of Arizona in Tucson. I did my medical school and residency in Egypt, and I did one year of

research at University of Nebraska. And currently I am a partner or like a member at the Clinical Problem Solvers, and I'm happy to be with you. Joining her is Dr. Fariba Donovan I'm Fariba Donovan. I'm Associate Professor here at the University of Arizona. Great to be here with you. I'm grateful that you actually are interested in Valley Fever. Hopefully doing this, raising awareness, that is one of our major goals on taking care of these very complex patients.

Thank you again for having us And rounding out the team is Dr. Tom Erwes. Hey everyone, I'm Tom Erwes, originally from France, but currently live in Tucson and working at University of Arizona as part of the infectious disease faculty, where it is very nice and warm. We're enjoying the sunny weather, it's a pleasure to be here. I've listened to a lot of Febrile podcast episodes during my fellowship, so it's a honor to be here as part of, uh, you know, later in my career training.

Thanks. Well, as everyone's favorite cultured podcast, before we get into the cases, we always ask this little question, to have our guests share a little piece of culture, just something outside of work that brings you joy. Uh, maybe Taghrid, I'll let you go first Yes, sure. Uh, so I love hiking and watching sunsets, and one of my favorite memories was seeing the sunset from an airplane window. Like, watching the sky change colors above the clouds was such a peaceful moment

Um, for me, ever since I moved to the United States, I've been trying to get all the national parks done, and recently I did Petrified Forest National Park in northern Arizona, was amazing. It was beautiful, and it was very empty. All the trails were clear of folks and had a great time. Otherwise, I'd say Acadia and Badlands are up there with my favorites. Yes. It's always the best when you have a trail or a little area to yourself. There's no one there.

It's so great. It's the best. Uh, Fariba, what about you? I'm thinking about which one to pick. I enjoy swimming a lot, and I enjoy golfing. And whenever I have a little bit of time here, uh, amongst other things I do, I, uh, try to squeeze an hour of swimming here in our rec center, and I invite everybody to come and join us. We have a beautiful swimming pool here that a lot of, uh, Olympic swimmers train in. So come and join us Very nice. Well, as you guys have already mentioned, we're very excited.

We're gonna talk through a couple cases related to Valley Fever today. So, um, Taghrid, I will hand it over. Let's get started Absolutely. Uh, so let's dive into our first case. Our patient, she is 28-year-old African American woman from Tucson, Arizona, with no significant past medical history, presenting with progressive right-sided chest pain and shortness of breath. About a month ago, her symptoms began like right-sided intermittent chest pain.

At urgent care, they thought it was just a muscle strain. She got pain medication, muscle relaxant with minimal improvement. When her pain returned again, they tried a course of antibiotics, but still no relief. Things getting worse, like more pain, cough, shortness of breath, and she went to the ER for evaluation. All right. So we're getting our, our typical ID call. Something seemed like it was okay, benign. Things are getting worse. So at this point, what are you thinking is going on?

What might be causing those symptoms? So I usually think about, like, if the patient is immunocompetent or immunosuppressed. In this case, it seems like she is immunocompetent patient, so I think about viral infection such as COVID or flu, maybe bacterial pneumonia. I might consider TB and need to assess the risk factor for TB, and definitely, like, endemic mycoses such as Cocci, given that she lives in Arizona.

Since Cocci is on my list, I ask about symptoms that might suggest dissemination along with the respiratory symptoms. Things like headaches, neck stiffness, confusion, vision changes, back pain, or skin lesion. But she didn't have any of those, and she also doesn't have diabetes or not on steroids, and she is not pregnant, so no obvious risk factor for weak immune system. So Dr. Donovan, can you talk us through risk factors for getting Cocci,

especially in places like Arizona? Absolutely, happy to do that. So I just wanna give an update or an introduction to the audience here. As you know, Southwest United States, Tucson and Arizona included, are very endemic for coccidioidomycosis. And, in overall numbers that we talk about, roughly about one-third of people who come to our emergency room with respiratory symptoms and

we call them CAP, community-acquired pneumonia, could be cocci. So our main effort, as I mentioned earlier, is to raising awareness. So anybody who comes with these symptoms, not to exclude your primary diagnosis, as Tagrid said, given the time of the year, maybe flu, maybe some bacterial pneumonia. However, please, please, please, don't forget to test for cocci. Believe it or not, we did a study and out of our urgent cares here in

Maricopa and Pima County, and we could increase, just by raising the awareness, we could increase the number of cocci diagnosis from 5% to almost 50%. It's a simple blood test that we do nowadays, and hopefully we are working towards developing a rapid lateral flow assay with a urine test that would be 15 minutes max to take. But just hold off on that thought until we have it in the market. But until that time, please just think about cocci and just simple test.

And the other thing I wanna tell your audience is that if people really think about this and they don't have access to their physician, they can go to Sonora Quest lab in our area and ask for the test. Arizona allows that. You don't need a physician order for that test. And even if you have no insurance, it costs about $40 to get it done. And if it is positive, it goes to your physician, or they call you and say, "Hey, go to the emergency room to get tested or to get advice what to do next."

So her social history is notable, she lives in Tucson, Arizona. She works as a teacher. She enjoys hiking. She doesn't have any history of smoking, drink alcohol, or use drugs. No history of homelessness, incarceration, recent travel, or known exposures. Her physical exam, she appeared ill and required three liters of oxygen by nasal cannula, maintaining oxygen saturation of ninety-seven percent.

She was afebrile. Lung exam revealed decreased breath sounds at the right base, and no skin lesion or neurologic deficits were found. Her initial labs, including CBC, CMP, were unremarkable. Influenza and COVID-19 testing were negative. Her chest CT showing a large loculated right-sided pleural effusion causing lung compression, as well as scattered ground-glass

opacities and possible lymphadenopathy All right. So we have a lot more information now. What do you guys think about our differential diagnosis? So at this point, looking at the whole picture together, obviously we wanna look at our common pathogens, and we ruled out COVID, flu, which is good given the ground-glass opacities on imaging. You know, bacterial infection still possible, but the timing of symptoms, the lack of leukocytosis, no fever, all makes it less likely.

Now, with the patient having symptoms for over a month, the imaging findings, the increase in adenopathy, so the big things to get concerned about and that you wanna rule out is gonna be TB, obviously. But with her risk factors, no history of homelessness, incarceration, travel, less likely. So the biggest flag here is gonna be her living situation in Tucson, Arizona, which is definitely gonna put her at risk for coccidioidomycosis. And more than thirty percent of community-acquired pneumonia actually in

Arizona are usually due to valley fever. All right. So we started here on broad-spectrum antibiotics. Thoracic surgery evaluated her, and they did decortication and chest tube placement for the loculated empyema. . So bacterial cultures of the fluid were negative, but the fungal culture from her pleural fluid grew coccidioidomycosis. Her blood test confirmed it was coccidioidomycosis based on IgG, IgM cocci serology with high complement fixation of 1:132.

We initiated fluconazole, and we stopped the antibiotics. So Dr. Erwes, what is the most common, um, leading like to delayed diagnosis of valley fever? Yeah. So a lot of patients often get misdiagnosed with other types of infections like viral or bacterial before the appropriate testing is done for diagnosis of valley fever. A lot of this is gonna be with the physician's level of comfort or not getting the right history from the patient.

So in the United States, the areas where one can find cocci is evolving constantly, so it's always great to get a good history of their travel and exposure. Often patients get a delayed diagnosis because the level of comfort with the different diagnostic tests out there, things like serum antibodies, complement fixation testing, whether or not a positive antibody test is gonna rule in the disease. But really, at the end of the day, the most important clue to make the

diagnosis will be the right clinical picture with the right exposure. Yes, absolutely. So Dr. Donovan, could you describe the risk factor for disseminated coccidioidomycosis? Absolutely, happy to do that. So going back to her history, as Dr. Erwes said, first and foremost thing is what I always ask patients is the travel history, and it's not only here in U- United States. We have patients calling us from Egypt, from Eu- Europe, from

Greece, from France, from Germany. People come here because of the beautiful nature that you just mentioned. They come, they visit us, and they leave, and then they have this very peculiar presentation that mimics other diseases, as Dr. Erwes mentioned, similar to, say, bacterial pneumonia, to viral pneumonia, to something that physician can't figure out, and this patient's disease goes on and on. In our study, we showed that even for disseminated disease, we have about

median of forty-two days of delay in diagnosis just because of that. So not only because people fly back to their home country and people don't know about the disease, believe it or not, here in our center, people get missed because people don't think about this. Now, you asked about the risk factors for disseminated disease. Certain genetic ethnicity backgrounds, such as African American and Filipino background, or people who are from Southeast Asia, put them at a specific risk.

And if you can look at the studies that we have done in, uh, recent years or in the past showing the genetic background that may predispose people to certain disease such as Cocci. The other thing is any immunocompromised state, and when I say that, it's not only people who have cancer and go on chemotherapy, but also people who have autoimmune disease and go on certain medications such as TNF inhibitors. We have done studies, it's published, that shows lack of TNF or suppression

of TNF pathway will increase the risk of, especially for patients with d- dissemination increases their risk. So, other risk factors such as pregnancy is one of them that actually increases the risk. Um, people who are diabetic have higher risk of potential pulmonary disease. So, for this patient really is a it's a good lesson to learn for all of us that if somebody comes in, meets the criteria and it's very peculiar

presentation with all negative routine data, just think about Cocci when you are practicing here in our area. And as I said earlier, it's just a simple test. So, um, if you are on East Coast, Quest Lab has the Valley Fever serology. If you are on West Coast, Sonora Quest has the cocci serology and CF titer. If somebody has weird headaches that don't go away, do a CT imaging to rule out hydrocephalus, and if you have the means, do a lumbar puncture and do a CSF study,

and that way you are on the right path. And then we are always available. Valley Fever Center for Excellence website. We are here for you, and if you need any question, we are always available to answer that Yeah, that's excellent. I'm very excited about this episode. I've only had one case of coccidioides that was a surprise in a patient who was visiting from Arizona. But you know, many of our listeners are gonna be practicing outside of Arizona or even the Southwest US, so I thought I would just ask in follow-up. You've already mentioned several sort of teaching pearls, but things for

folks in non-endemic regions to think about either with a patient who's had persistent pneumonia symptoms or, it could also just be another general sort of tip or recommendation when thinking about coccidioides Yeah. I think the point that we definitely bring across is if someone comes in with these persistent pneumonia symptoms and they've gotten multiple courses of antibacterials, definitely should look more into their prior travel history. And, you know, for those that learned the CDC maps from a few years ago, I

think it's always a great idea to just review the most updated maps and see which endemic fungal infections are found in which part of the country these days because it continues to expand every time Feels like the party line to say that the maps are evolving on every episode or every other episode You know, I wanted to add something to what Dr. Erwes mentioned. Samantha Williams just published a paper in, uh, JAMA Network talking about the expanding burden of cocci.

And if you look at the map that she has, and if you look at the map in CDC, and also there is a flowchart in CDC website talking about if you think about cocci, what to do, and how to approach these patients. That would be really good, and we try to keep both of those two, uh, websites updated regularly, both our website and the CDC website. So stay tuned Uh, well, Taghrid, can you tell us a little bit about an update on this patient? How long do you think you're gonna treat this patient?

Absolutely. Um, I have just interesting updates regarding her. You know, like coccidioidomycosis just surprising me every time I have patient with coccidioidomycosis. So in her follow-up clinic visits, she reported new chronic headaches, which have been manageable with Tylenol. Her complement fixation titer was elevated at 1:520, raising suspicion of coccidioidal, uh, meningitis.

So we asked for having brain MRI and having LP to rule out cocci meningitis, which will helpful for, um, duration of treatment - but MRI and LP were reassuring, and she didn't have cocci meningitis. However, she developed chest pain and shortness of breath, and she was hospitalized. We have CT scan and MRI, and both of them showing large heterogeneous right

posterior pleural mass, and this mass extending into the chest wall, paraspinal musculature, and spine with additional erosive changes involving the right tenth rib and the thoracic ninth vertebra. All of these findings consistent with disseminated coccidioidomycosis. So we have our colleagues, IR did aspiration of this collection, and the culture showing coccidioidomycosis.

However, she was surprising. She was on fluconazole, and she was taking her medication and still having disseminated coccidioidomycosis. So in this time, we treated her with Amphotericin and we switched fluconazole into itraconazole, as there is some data about using itraconazole for cocci involving bone. And we discharged her into itraconazole. And regarding the duration of treatment for coccidioidomycosis, it

depends, if there is dissemination, and if there is dissemination, where is the dissemination in? So if she has cocci meningitis, so for sure she will be on antifungal for life, as meningitis cocci, is lethal, so she needs to be on antifungal forever. But here dissemination while she was on antifungal and the dissemination into bone is just concerning. Especially, she has the risk factor for dissemination being

an African American woman. I think in her case, if we continue the treatment until having all of this mass resolved, being under control. But disseminated cocci in bone tend to relapse again after stopping antifungal. I think in her case I don't feel comfortable to stop, to think about the end of therapy for her. I think we need to have shared decision-making. So I would like to ask Dr. Donovan about her opinion

Well, thank you again. Number one, we know about three to five percent of the patients who have cocci, they develop dissemination. So just looking at it, you think, "Well, that's not a big deal," right? It's only three percent. It's a local disease. And that's what we hear when we submit grants for continuing our research. But actually, when you think about it, uh, the total cost to our area is 1.2 billion, and I'm not talking about million, billion with B, dollars a year is

the cost of the care for these patients. So it's not really a simple, uh, neither the physiological and healthcare related burden, but economic burden to the area. So we really have to kinda change our old mindset and think about this disease a little bit more seriously, the problem with the treatment, as just, uh, Taghrid mentioned, is that the disease so far, the medication we have is all fungistatic. So unless so- you put somebody on amphotericin for life and I'm gonna pause

that, um, you have to treat these people for life, especially for cocci meningitis. Now, you imagine somebody who's 20-some years old, you're gonna give them minimum of four pills a day, maybe eight pills a day of fluconazole, or you switch to posaconazole with all the side effects that come. So, um, yes, the treatment is lifetime if all we have is what we have in the market. However, looking at potential other options, and I don't know if you have

heard, your audience have heard about other new antifungals in the market. I have this paper here for you, October 31st, 2023, New England Journal talking beautiful table and picture of all the antifungals that are out there now, including new and old. And one of the med-medication we have that is currently in the process, hopefully, of FDA approval is olorofim dihydroorotate dehydrogenase inhibitor

that blocks pyrimidine synthesis, so it blocks both DNA and RNA synthesis. In animal study, it shows that it is fungicidal. It's a pill, and, um, really very minimal side effects. You have to monitor liver enzymes, but to this day, all the patients I have studied, so far only one of them, we had to take him off of the medication because of liver enzyme abnormality. Otherwise, you can adjust the dose, and they will tolerate it. Amazing medication.

I have several other studies ongoing. We have a paper coming up in, um, Annals of Internal Medicine specifically talking about olorofim in cocci patients. It's really a valuable medication to, to use for studies. Um, the other medication is fosmanogepix, which is GWT1 inhibitor. It works on the cell membrane and blocks that. I think it is fungistatic as far as we know. We have used that medication for our patients.

Dr. George Thompson from UC Davis published the paper on nine cases with great results. Um, we have had a couple of patients. Unfortunately, the GI intolerance caused the discontinuation of medication on our end. But, you know, there are other agents out there that are in the phase one or phase two studies to see if we can these medications go through, hopefully get FDA approval. One other thing I wanted to talk about is the patient advocacy groups.

There are a lot of groups out there. Uh, patient developed this Facebook team or group of patients that they talk about their own experience. So, um, again, for your audience, we are available. They can reach out to us, and they can reach out to this patient advocacy group if they wanna get the information firsthand, you know. Um, sorry, I keep, uh, I, I am very compassionate about this disease and can't stop me when I start talking about it. So please interrupt me if you want.

That's perfect. Well, you also mentioned, um, Dr. Thompson, who we've only had one other episode I think that specifically talked or focused on, um, cocci valley fever, uh, which was a collab with MSGERC. Oh, it's always an alphabet soup, yeah. Um, um, but if folks wanna check that out, it was episode 115 I think will be a really nice complement to these. Um, perfect. Okay. Well, it's, it's good you were talking about we may, you know,

touch on some of those points later with our subsequent cases. So Taghrid, how about you take us onto the second case you've prepared? Absolutely. Uh, so let's move into our second case. So we have a fifty-five-year-old Vietnamese man. He has well-controlled HIV on dolutegravir and lamivudine. He has poorly controlled type II diabetes and hypertension. Also, he has a history of ortho disseminated coccidioidomycosis on

posaconazole and prior syphilis. He presents with worsening chronic right knee pain and swelling. More history about his disseminated cocci. So ten years ago, he was diagnosed with disseminated coccidioidomycosis. He had miliary lung disease plus adrenal and splenic involvement. Two years after, he had dissemination to the right knee and was confirmed by biopsy from the right patella, which showed coccidioidomycosis.

He has been on posaconazole three hundred mg daily since then, with good response for years and maintained appropriate therapeutic level. In terms of his social history, he is Vietnamese, moved to the US in nineteen ninety-two. He has lived in Tucson for the past twenty years. He enjoyed outdoor activity, um, including hiking and biking. He worked an IT staff member in the military

All right. Well, I mean, we're a little biased because we know what this episode's about, but tell us about your differential, right? It's a little unusual. Chronic knee pain, swelling, um, so what are you thinking about? Yes, absolutely. If someone is like, if we are biased for coccidioidomycosis, like if someone is on antifungal, so I think it be coccidioidomycosis? And the answer is usually yes. Uh, so it's top of the my list is coccidioidomycosis itself. Either there is insufficient source control, or we might be

dealing with treatment failure maybe poor antifungal adherence. Other differential diagnosis such as TB is possible, but he doesn't have, like, clear risk factor for exposure history. And we also need to consider bacterial septic arthritis, so it's important to rule out gonorrhea, like septic arthritis. Other causes like brucellosis if he had recent travel or animal exposure such as goats or sheep, cattle.

but yeah, for sure, like non-infectious causes such as crystal arthropathy as gout or pseudogout or malignancy Perfect. All right, well, let's hear a little bit more about the exam and the labs and other info that you found Mm-hmm. Sure. So his vital signs are within normal limits. On physical exam, his right knee is swollen, red, and warm. The other physical exam is unremarkable. CBC, metabolic panel was in normal limit.

MRI shows interval progression of the right patellar osteomyelitis with extension into the distal quadriceps and patellar tendon, along with new tibial tuberosity osteomyelitis, intra-articular spread causing septic arthritis and concern for pathologic patellar fracture. So Dr. Donovan, can you help us to narrow our differential diagnosis? Well, absolutely.

So as you just mentioned, if I see somebody in the clinic calling a general ID clinic, not a valley fever clinic. Common causes are common most of, most of the time. So strep, staph, the right population as you just mentioned, gout or pseudogout. again, the right populations. Gonorrhea could be an, a factor. Other causes such as, you know, those atypical Brucella. However, you know, malignancy you mentioned, absolutely we

have to keep that in mind. This patient is an HIV, but well-controlled, I assume. Some of those risk factors automatically get excluded because it a- appears that patient is very adherent to his regimen and routine follow-ups. Now you mentioned that the ethnicity is Southeast Asian, so, um, now I'm putting my valley fever hat on and I say, "Oh, this is valley fever," until we prove it otherwise. One thing that for your audience I want to emphasize is that valley

fever causes dissemination in joints, usually it's asymmetrical. The difference between early valley fever, early coccidioidomycosis, that what we call desert rheumatism, is an immune response that you could have migratory arthritis. It goes from one joint one day to another joint another day. But if you tap those joints, even if they are swollen, usually they are negative. So please don't do that yet, and just wait a little bit to see if this patient actually has dissemination to that joint or not.

What's the differentiation with this is usually if you have a septic joint that is caused by valley fever, usually it's asymmetrical, and you have all the other criteria related to a septic joint but it's not as acute. You have a staph aureus septic joint. It's hot, it's red, it's acute. Patient have a lot of pain. They can't walk on it. Somebody with septic joint with cocci, they could be walking to your office and they just have some pain, but it is asymmetrical.

And remember, if you tap that joint, you may not get a positive culture. Usually what we like to do is get a synovial biopsy and look at the spherules in that area. So that becomes a little bit more complicated, especially for patients who are in non-endemic area and the orthopedic surgeons who are in non-endemic area. Well, nobody's gonna do that for a joint that is semi-septic, you know. And you have to have the right surgeon who is familiar with this

disease to, to agree to do the biopsy. Always you can, uh, rely on your CF titer and serology to say, "Hey, this patient has a CF titer of 1:250, well, and this joint is hot and swollen and has fluid in it, . again, going back to travel history, your examination, and then the risk of the genetic risk factors come very handy when it comes to differentiating this from other causes of septic joint

Perfect. Yes, I agree with you, we need to have more physicians and surgeons who are familiar with this disease. So Dr. Erwes, based on the MRI findings, what, what make you particularly concerned for active coccidioidal bone and joint disease? Yeah. So we keep bringing up the clinical picture, and before even getting to the MRI findings we do wanna look at the history, the patient to make a diagnosis of disseminated cocci to the bone.

So take the patient with prior history of pulmonary cocci with or without dissemination, especially if there's a concern for immunosuppressed status or ethnic risk factors now presents with new persistent bone and joint pain, definitely consider for musculoskeletal involvement of valley fever. On MRI, you know, think almost like TB and can present all kinds of ways, but some of the things we tend to see with cocci for bone involvement to have

more of a lytic destructive process. It can show up as an osteomyelitis, and in more progressive cases lead to actual pathologic fractures like our patient. In regards to joint involvements, the patients can present with persistent effusions and eventually also develop erosive arthritis. So our patient really met a lot of those criteria, both from the clinical picture, the background, and those MRI findings that all kind of pointed towards, know, musculoskeletal involvement of valley fever

So he underwent arthrocentesis, and the fluid was yellow and hazy with cell count of four thousand, with fifty-two percent of neutrophils, thirty-seven percent of lymphocytes. based on the clinical picture, synovial fluid findings, there is no clear evidence of bacterial infection, and we recommended against antibiotics. We also sent Coccidioidomycosis serology, complement fixation titer and cultures as well.

We also obtained posaconazole serum level to make sure it was therapeutic range. Because of concern of severe disseminated cocci, we started him on amphotericin B, five mg per kg, in addition to his ongoing posaconazole. And what'd you hear back on the posaconazole level? It was surprising. His posaconazole level was normal, with an therapeutic level 1.9, but Coccidioidal IgG was positive with complement fixation titer 1:8.

Synovial bacterial cultures were negative, and syphilis RPR was non-reactive. But the fungal synovial culture growing cocci- Alright. And, I think this is really interesting. Like, how do we think about recurrent or worsening septic arthritis? We have cocci here again. This patient's been on posaconazole with therapeutic level. Uh, how do you tie this all together for us, Dr. Donovan? Well, this is a great question we always get that, is this a resistant strain?

I really want to emphasize on this. There is no clear cutoff for the MIC for cocci with different antifungals. is a study was, uh, done, I think it's published 2019 by Dr.. Thompson, and he compared different strains that they had in their lab of cocci against different antifungals. And the only antifungal had higher MIC at lower doses was fluconazole. For the rest of the antifungals, it was really reasonable MIC.

So generally speaking, first of all, our patient population, when they say they take the medication, they have suffered so much that I truly believe that they remain adherent to the regimen. Two, I don't except a couple of specialized labs that do the MIC, I don't know if anybody else does that and how reliable that MIC testing is. So the question is, if the level is fine, it's really not the efficacy of

the antifungal, but it's the source control that has to be mentioned. So in here, as you know, the, the cocci is still already in the synovium. It's already in the joint. So as long as this remains in place because your antifungal is not cidal, it, it's gonna remain there. And as the moment that back off the an- antifungal or the dose goes down, or the metabolism goes high, so you have transient lower level, this gonna grow back.

So under these circumstances, sometimes I either go up on the dose and push it to higher blood level or I switch the regimen. Maybe this patient is metabolizing this too fast. if you have the reliable lab that can do MIC, go ahead and send that, but I wouldn't rely on that really. I probably have sent two strains for MIC testing. the other thing is, think about these new antifungals in the market.

Maybe that would be a solution for a patient. the other thing that I really want your audience to think about is as Taghrid is doing, get a level. Uh, levels are very easily done. Uh, most labs do it, fluconazole, itraconazole, posaconazole, both to avoid the side effects and to kind of monitor the, the, the response to the treatment. Thank you, Dr. Donovan. So Dr. Erwes, when I was thinking about this case, reviewing what happened,

initially he had this diagnosis of dissemination in the right knee, which was diagnosed with biopsy, but he didn't undergo I&D (irrigation and debridement). But after that, he came again with this dissemination. So should he have undergone I&D when he was diagnosed earlier the first time so the patient wouldn't have active disease? And what do you think about the role of orthopedic surgery? Yeah, it, it's always easier to say things should have been done differently in

Yeah hindsight but before addressing any kind of surgical intervention for these patients, it's always important to make sure, first of all, they're on the right and appropriate antifungal therapy, the right dosage, they're adherent to it, there's no interactions with any other medications. Like you said, when there's significant involvement, once there's a lot of burden of disease, it's often unlikely to resolve without any kind of intervention with just antifungals alone.

And, you know, with debridement, it's not only gonna help the chance of disease resolution by decreasing that burden but for our symptoms, it's also gonna help provide a lot of symptom improvement And I think the other interesting learning points from this too, from this case, it, you know, taking a step back maybe more globally is, thinking about cocci in the context of a patient living with HIV. And I was wondering if you guys could talk a little bit about that, using prophylactic azoles. You know, when do you treat?

How do you treat? When is it okay to stop? I know there are guidelines available, but I would, um, feel confident in saying that I'm sure there's a lot of gray zones there, uh, and, and sort of tricky areas where you're doing some shared decision-making Certainly. So there is guidelines for the prevention and treatment of opportunistic infection in patient with HIV. So if the patient have a new diagnosis of HIV or have diagnosis of HIV, and

he has cocci serology positive, his CD4 count will determine if the patient will need preemptive treatment or no. So if the patient have CD4 count is less than 250, we start preemptive fluconazole for this patient. This will be continued until he has undetectable viral load, being asymptomatic, CD4 count is more than 250. That is generally a patient with HIV and cocci serology positive.

But if the patient has already cocci with symptoms and this cocci disseminated, so it's based where the cocci was disseminated to. Like if the patient cocci meningitis for sure will continue forever regardless if it's like HIV or no. If the patient… If this patient, he has disseminated orthopedic coccidioidomycosis, so regardless of the underlying comorbidities such as HIV or CD4 count, they tend to relapse after stopping antifungal.

So in this case, I prefer to be in the lifelong suppressive antifungal. So, Dr. Donovan, what is the risk of recurrent cocci That's a very good and loaded question. Where should we begin? So remember, when you catch or even when you are exposed to arthroconidia in the environment, if you acquire the disease, you will always have the disease, or I should say you will always have the fungus in your body.

The good news about that is once you catch the disease and the arthroconidia, you develop lifelong immunity. Under normal circumstances, that lifelong immunity lasts for life, right? And the other aspect of the disease is 60% of cases that get exposed to it, they don't even know they had the disease. A very, very subclinical, 60%. That's pretty good, you know. About 30% of people develop some pulmonary symptoms, and those are people that

either come to my clinic or your clinic. Those 10% are the one that get so sick that they come to the hospital, potentially have pneumonia, like your first case, right? And then out of those 10%, three to 5% develop dissemination like this case. Now, the dissemination we just talked about, the, the, the risk factors are there. We just discussed that. I don't wanna repeat myself again. Now, what is the risk of recurrence? It's when that immune status that keeping this, uh, at bay and on hold goes away.

What are those causes? Well, HIV/AIDS is one of them. If somebody has been in the area and has been exposed and never had the symptom, and all of a sudden is diagnosed with AIDS, well, certainly they are at risk of the re-reactivation rather than recurrence. These are two different terms. Re-recurrence is you catch it again, and we believe, uh, that once you develop the lifelong immunity, you don't catch it again. However, if you have the latent cocci in your body, you could reactivate.

And the reactivation again is when somebody goes on TNF inhibitors, on, uh, uh, JAK inhibitors. They are on chemotherapy. They get pregnant. So all of these clinical status that are causing your immune system to get suppressed could potentially, uh, make this disease reactivate. And then how do we deal with that is think about it because then at least you can prevent it from getting totally out of hand

Excellent. All right, we're on to our third case Absolutely. So our patient is a fifty-eight-year-old man with history of alcohol-related cirrhosis. He has had several weeks of worsening headaches, general weakness, confusion, and overall decline in mental status. We don't know much about his social history, except he lives in Tucson, Arizona, now we know, like, what is the case about.

So on arrival, he was afebrile and stable, but unfortunately, his mental status kept getting worse, and he eventually needed to be intubated. On exam, he was encephalopathic. Cranial nerves were intact, and there were no obvious focal deficits. He had EEG, showed global encephalopathy, but nothing pointing to a specific cause Okay. Again, we're keeping an open mind. Maybe it's not valley fever, coccidioides.

Uh, what else is on your differential? Yes. Um, yeah, usually we need-- even if we have this top of our list, it's coccidioidomycosis, we need to think about other causes such as viral, like aseptic meningitis, encephalitis, such as herpes zoster in a patient with liver disease and have, uh, like old age, maybe Cryptococcus meningitis. We don't know about him, like he might have an HIV or undiagnosed HIV and developing cryptococcal meningitis.

Maybe neurosyphilis. TB is always in differential diagnosis. But again, the top diagnosis on my list, uh, for someone living in Arizona is coccidioidomycosis. Additionally, given his age, maybe Listeria meningitis, and here sometimes we see lymphocytes and low glucose in CSF with hydrocephalus. And hydrocephalus in Listeria meningitis has been reported in about one in five cases.

And of course, metabolic encephalopathy, like especially with his liver disease. So Dr. Erwes, given the concern of coccidioidomycosis meningitis, what is the most common presentation of coccidoidal meningitis? Yeah. So the presentation can be kind of broad, but usually when we think of the hallmark symptom for cocci meningitis, these patients present with a persistent progressive headache, usually lasting anywhere from weeks to months.

It's definitely not as an acute of a presentation as what we see with bacterial or even viral meningitis. These patients tend to have more subtle symptoms, chronic fatigue, cognitive slowing, some confusion eventually. And then later on, you can get some more progression of the disease things like hydrocephalus, developing cranial nerve deficits, overall showing signs of increased intracranial pressure. So again, in an endemic area like Arizona, someone that presents with

these chronic headaches should make you think of, um, working up for cocci. then the biggest clues eventually are gonna be your CSF profile, which you'll be talking about in a little bit Yes. So we have initial labs. White blood count was thirteen thousand, uh, with mostly neutrophils. CMP was in normal limits. We had blood cultures were negative, but CT scan of the head showed moderate communicating hydrocephalus, and there is CSF flow through the brain tissue.

So he had a lumbar puncture, and CSF cell count was one seventy, with seventy-two percent of lymphocytes, eight percent neutrophils, and twenty percent monocytes. Protein was high at three hundred, and glucose was low at forty-five All right. Dr. Donovan, with these results, how are you thinking about this patient? Well, I, um, I like to keep my differential very broad and as Tagrid touched upon all of those.

You know, with his age and liver disease, I always wanna rule out bacterial meningitis somebody like this. So thank God that you did that and everything was negative. Now, looking at the CSF, generally speaking for cocci meningitis since that's the topic that we are discussing, um, one hallmark of these patients even before your CSF result come back, after you decompress that pressure, all of a sudden they wake up. They talk to you. They are just a different person before and after lumbar puncture.

Um, and I guess that is true for any hydrocephalus really. Now, in here, you, you will usually have pleocytosis, lymph predominant, eosinophil count sometimes is very elevated, especially in earlier stages of the disease, means cocci meningitis. You will have very low glucose and very high protein. So that also comes very handy when you look at the general CSF picture. The only two disease that has very low glucose are, your audience, one is

cocci and the other one is tuberculosis. They go down all the way to teens. So you really have to think about this, especially in this area. Now, how do we specifically diagnose a patient with cocci meningitis? Beside all of these clues is that you send a cocci antigen, not antibody, but cocci antigen to Miravista lab. The main lab is in Indianapolis. It's a send out test. It takes a few days to come back. It's highly specific, ninety-nine percent and ninety-nine percent sensitive.

So once you have that, then you could say, "Okay, I've got my diagnosis." Now, I would say that sometimes in early disease, the amount of antigen is not high enough for you to diagnose the disease. If you have every clue, all other clues in place, don't say this patient doesn't have cocci meningitis because that cocci antigen is negative. I would suggest you should repeat that again in case of negativity, but most of the time a patient comes with so much clinical presentation, it's always positive.

Again, pleocytosis, lymph predominant, very low glucose, and somewhat high elevated protein is the clue. And the, uh, the other thing is by decreasing the pressure, patient comes up and just wakes up and is totally different person than they were at the baseline. So if those are with the right circumstances, in the right setting, in the endemic area or a travel history, you got the answer Perfect.

Thank you, Um, so we have initial CSF bacterial, fungal, and AFB cultures were negative. Serum and CSF cryptococcal antigens were negative. Bacterial, fungal blood cultures also negative. AFB studies were negative as well. But serum and CSF cocci IgM, IgG were positive, and cocci antigen in CSF was positive, and CF titer was one to thirty-two.

So based on these results, we discontinued empiric antibiotics, and we started him on IV liposomal amphotericin B plus high-dose fluconazole. So, Dr. Donovan, can you walk us through, uh, your approach to cocci meningitis, especially hydrocephalus? I noticed that you mentioned the diagnosis. So can you walk abo-about the management of hydrocephalus? Absolutely. So, first and foremost, I'd like your audience to look at our

IDSA guideline written by Dr. Galgiani, our director here, 2016. You always have to have that on the side of your desk when you look at these patients, especially for people who are not familiar with the disease and how to approach it. But generally speaking, for this patient, what you did is perfectly the right approach. You do the, the lumbar puncture to prove the case. For these cases, I always call a neurosurgeon same time that I ask the neurology or radiology to do the lumbar puncture.

And the reason for that is, if this is cocci meningitis, I want our neurosurgeons to know the patient and be involved in their care from very early on. Like anything else that kind of is collected and has to be drained, so is the CSF. So a lot of these patients require shunt very early on to decrease the pressure and decrease the, sequelae that comes later on. So, you know, if the neurosurgeon says, "You know what? Let's just wait, no shunt yet," then I feel better that everything that I could for this patient to avoid

potentially long-term mental state changes because of the pressure that has happened. So firstly, you prove the diagnosis. Two, you will get the neurosurgery to come and comment and consult them. Three, what do we do about the antifungal? Amphotericin B is the one I always go with. And then in the meantime, because if you remember, all of our antifungals have a certain timeframe to get to the appropriate TK level.

So until that time, say if it is five days, if you say, "Okay, I started the patient five days ago on fluconazole," you really haven't treated them yet until five days from that point. So I put them on amphotericin that is immediately, give you some results. And then at the same time, you put them on whatever azole you like, the choice of your day. Could be posaconazole, fluconazole. And of course, your insurance consideration becomes a major point and hurdle.

So if you decide, "Okay, I'm gonna do fluconazole," what I usually do, do, I don't go with like eight hundred milligram a day. start with four hundred milligram. Now, different physicians have different approach. If I have amphotericin going, I start with four hundred and I keep both going for a whole week, I measure the level of four hundred. If it is too low, then I have a room to go up. I go to six hundred and go to eight hundred. The reason for that is patients develop very- severe side effects sometimes

earlier on, such as another headache that comes with the fluconazole. They can't eat. They are very dry. They lose their hair. So they really, you have to taper this up as as you see fit for that specific patient. if I had my way, I would use olorofim right away, and I would not go with fluconazole but I don't have that yet, so I have to live with what I got. Um, the other medication that I've seen patients actually respond

better is posaconazole, but again, insurance becomes an issue, so you have to look at your patient. But I think, um, sure you wanna get a neurosurgeon to look at this patient, see if they think this patient needs a shunt. Of course, it's a major stressor for patient, for somebody who's young and, you know, never been sick and all of a sudden now they tell him he has meningitis. that's gonna be somewhat of work on our side to educate the patient about

how important it is to prevent this from happening over and over again. and then the other part that I always want to monitor is, of course, their liver enzymes and the QT interval. If you have patients on, say, uh, fluconazole, posaconazole, you wanna look at the side effects see what is it that I have to monitor, what is the baseline. So I always take a baseline EKG on this patient, a baseline liver

enzymes, especially in this patient who is, has liver cirrhosis. Where do we go from there? Is azole safe or not? So, um, lots of measures that you have to keep in, in mind Yes. Thank you for sharing with us. I feel grateful to have my fellowship in this, like, endemic area from coccidioidomycosis, learning more about this disease. So back to his hospital course. While he was on amphotericin, high-dose fluconazole, his hydrocephalus

got worse, and he needed an external ventricular drain based on the neurosurgery evaluation. They CSF sample from this drain or from this shunt and they send it for analysis. Cell count were eighty-four, protein was three hundred, uh, glucose was forty, but infectious disease recommended to get the lumbar CSF sample instead of the shunt sample. So we have lumbar CSF studies for better evaluation.

So lumbar cell count was six hundred, protein was six hundred, and glucose was very low at ten And that's a really good, I think learning point for us to reinforce. Can you guys talk about why your lumbar and ventricular CSF results might have looked so different thinking about cocci? This is an amazing learning case for all of us. Uh, we have read it, it's published, several reports have been there, but

until you see it, you don't remember it. That, you know, when you have this, the inflammation, usually it's basal meningeal inflammation. So it's just like anything else. Below that level is where the markers of inflammation will be evident, right? Above that, it's maybe to some extent, but not as much. So on the contrary though, the, surgeons like the, the fastest approach that is least invasive, right? So of course, we have a, reservoir or we have an ex- external device in place.

So why not just taking a sample of that? Well, that's above the level that the inflammation, the pathology is going. And this was a great example that below that level is so different than above. So we always say to our fellows when they do the studies, the CSF on these patients, "Did you get it from lumbar puncture, or did you get it from the, the reservoir or the, uh, EVD?" And if it is from reservoir, we always ask, "Please, uh, try to get the lumbar puncture." We get it sometimes patients

are not, um, stable enough to do lumbar puncture or whatever the cause is, then we live with what we have. But keep that in mind always, always, the lumbar puncture is your final diagnosis. You may see some improvement in the EVD, but until you have the lumbar puncture, don't think that you have with stabilizing the patient yet. Usually, there are higher cells, cell counts. There are much lower glucose. There are much higher protein.

But generally speaking, you mentioned something, Taghrid, that I wanna emphasize on. Generally speaking, CSF cultures are negative uh, cocci meningitis. but, if you do MRI imaging together with lumbar puncture, basilar meningeal enhancement, or the some ventricular enlargement together with hydrocephalus and abnormal numbers in CSF, you got the diagnosis. So you don't have to wait for the result to start the treatment

Perfect. Thank you for this. So continuation of hospital course. So he underwent a permanent ventricular peritoneal shunt placement, initially, he has this external ventricular shunt, and I know, like, we discussed this, uh, multiple times, and the treatment, one of the most important for him is to have permanent VP shunts, in this cocci hydrocephalus. So after about ten days of being on ventilator, he improved and

was successfully extubated. Liposomal amphotericin was discontinued after two weeks, and he remained on high-dose fluconazole but he developed QTC prolongation, so we switched him into isavuconazole for lifelong therapy So we talked a little bit so far about the role of neurosurgery, but I wanted us to just pause and make sure we summarize again, why so many of these patients require permanent shunting and other long-term complications that you're

thinking about in patients who have VP shunts placed for coccidio meningitis. Uh, so I will throw that to you, Dr. Erwes. I know that's a big question, but, um, tell us what your experience has been. like Dr. Donovan mentioned, it's always good to get neurosurgery involved once we get these consults for symptomatic cocci meningitis, and the longer this goes untreated, the more there's gonna be that basilar inflammation, the scarring that's gonna overall impair the flow of the CSF, impair absorption.

And like other causes of hydrocephalus, the main management, other than the underlying source, gonna be relieving the obstruction that's impeding the CSF flow. So whenever we have our amphotericin B, it's gonna help treat the underlying cocci infection. all that buildup of pressure from the inflammation, needs to be managed with, uh, shunting. Usually it's gonna be done with VP shunt. Any hardware insertion in the world of infectious disease comes with its own

risks, and, you know, the longer these patients have a VP shunt, the more risk of complication that comes with as well. When it comes to complications from VP shunt placements, it can be both from a neurosurgical complication like shunt malfunction, obstruction, which eventually those will need shunt revisions, but there's also infectious complications. Now, if the patient's on appropriate antifungal treatment, they're adherent, they're less likely to be at a risk for worsening cocci infection, but you have

hardware in place, and there's always a risk to get superimposed infection with something else, which we often see. Some of our common bacterial infections for these VP shunts, anything from our Staph Cutibacterium. So in terms of when you wanna think about repeating a CSF analysis in someone that's been on treatment for cocci, has their VP shunt, if you're concerned for a new infection, wanna look at the clinical picture. Are there new fevers? Is the imaging concerning for poor flow of the CSF?

First of all, you'll check with your neurosurgery colleagues. Is there concern for mechanical obstruction? If not, then you wanna repeat that CSF and see if there's anything else that shows up in your culture that you might want to treat. If I may add something to what Dr. Erwes said, for the area out of endemic area that the neurosurgeons are not as familiar with the disease, this is not one of those cases or diseases that say, "Oh, let's wait until the clearance of CSF before

we put the VP shunt," because if you wait, patient has to go home with an EVD. It is not gonna clear that quickly. This is a different kind of disease, so we try and we see that a lot of times here when our colleagues come from outside of the endemic region. That's the practice, and we understand that. But that doesn't apply to this disease. So once patient is stabilized clinically, they should get the, permanent shunt so they can actually be moved out of the hospital and start their rehab

Right. And you've already mentioned some of these, but we do towards the end like to ask questions about the landscape, what's on the horizon. So what should we remember about emerging antifungals that are available? So one of the med-medications that we have right now that is hopefully close to become FDA approved is olorofim. And I have had great experience with it. Uh, this will be, I think just like when fluconazole came in the market

for patients, and all of a sudden we saw that patient actually survived this lethal disease, this is gonna be the next generation of fluconazole. It's not azole, but it's gonna be a major game changer for all these people. There are other agents that are in the market, some of them closer to become phase two for clinical trial, and some of them are not yet. But stay tuned because, we have cocci study group meeting in August

this year, and we have mycosis study group meeting in September, and then we have ID week, and we have a lot of presentations on that regard. It's hard to condense everything in a few minutes, so bear with me and stay tuned. All right. And then what about a vaccine for coccidioides? Well, we have a, an avirulent strain of cocci, we call it Delta CPS-1, which was developed by actually a mutation that was done on a different fungus, maize fungus.

And they saw that actually that mutation on this gene changed the fungus into avirulent, and they could save the corn. So when we or our colleagues here, Dr. Urbach, looked at the homoge-hom-homogeneity of that gene in cocci, we saw actually homologous genes in cocci. So by mutating the gene, we saw the same result. Our avirulent strain we call it Delta CPS-1, is alive.

It grows the first life cycle, and then it falls apart. By doing so, actually it induces the immune response in both murine model and in dog. so, very minimal local and side effects. We need to boost, one is the original vaccination and then a boost, um, I think they do it in six weeks in dog. And we show that when these dogs are vaccinated with, with this strain, and

then we give them inhalation model of the virulent strain, they don't get sick. And this was even done with the mice that is totally, um, immunocompro- compromised, doesn't have B-cell or T-cell, and still did the same thing. So we are very excited about this. There are aspects of vaccine development that still is in progress, and hopefully soon it will be through our partner, industry partner, to

develop the vaccine for canine, you know, for dogs mainly in the area. And then hopefully the next step is to find some other industry partners for human vaccine development. But as you know, human vaccine development has a lot more cover. We have to make sure it's safe. We have to make sure it doesn't have adverse events. And of course, uh, the minimal side effects with the maximum immunity is what we are looking for Excellent. Any additional closing thoughts before we wrap up?

I'd like to thank you for having us, uh, to share a little bit about coccidioidomycosis and just keep in mind to have cocci in your differential diagnosis if you are in endemic area. If not, just ask about travel history. If in endemic area, you need to keep in mind cocci. One very, very small point I wanted to make is if you look at our IDSA guideline, not everybody who comes in with cocci presentation needs treatment,

but you do need to diagnose it. People, a lot of people with pulmonary cocci, we don't start them on treatment. We monitor them unless they are really severely ill, and they need treatment. And one study that has been done by Dr. Ampel in 2009, CID showed actually people who got started on treatment in two years follow-up, they had higher risk of dissemination versus people who didn't get the treatment. So we treat when we need it, but we take it very, um, considerably not to treat

if we can't avoid, if we can avoid it. So it's just the, the question that when do you need the treatment? Not everybody needs antifungals to avoid effects and to avoid potential, uh, down the road issues that comes with the treatment. Thanks so much to Taghrid, Fariba, and Thomas for joining the episode today. Don't forget to check out the website, febrilepodcast.com, where we house our consult notes, which are written show notes of the

episodes with links to references, our library of ID infographics, and a link to our merch store. Febrile is produced with support from the Infectious Diseases Society of America. Please reach out if you have any suggestions for future shows or wanna be more involved with Febrile. Thanks for listening. Stay safe, and I'll see you next time

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. 136: Single-Payer Healthcare Through an ID Lens

    Oct 12, 202638 minAudio

    Febrile is joined by Drs. Brian Bramson, James Lewis, Christian Hendrix, and Erica Kaufman West who discuss an all-too-common scenario and explore how single-payer health care systems may impact ID practice. Learn more...

    Credit the people on this episode

  2. 135: Most Missed Qs with PIDFC Spring 2026 Champions

    Sep 28, 202645 minAudio

    Sara and Marisu Rueda Altez (University of Alabama Birmingham) chat with the Pediatric ID Fellows Cup (PIDFC) 2026 champions “Sweet Home Histoplasma” (team from UAB) and “RBC BugBusters” (team from Rainbox Children’s...

    Credit the people on this episode

  3. 134: A Day in the Life: ID Private Practice

    Sep 14, 202637 minAudio

    Drs. Manuel Rodriguez and Manuel Castro-Borobio join Febrile from Georgia to chat about a day in the life of an ID physician in private practice and questions and considerations for new fellows consulting on the job...

    Credit the people on this episode

  4. 133: Pump and Circumstance: An update on VAD/MCS infections

    May 11, 202624 minAudio

    Drs. Alok Nimgaonkar and Rebecca Kumar provide an update on definitions for VAD infections! Also mentioned in this episode is a call for the new Febrile Editorial Board!! You can find more information at...

    Credit the people on this episode

  5. 132: Not Your Average Brodie

    Mar 30, 202614 minAudio

    Drs. Veronica Santos, Sebastian Shrager, and Misti Ellsworth share a not so typical case of Brodie abscess! Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com Febrile is produced with...

    Credit the people on this episode